Sign In
Buy BPSR
$0.0200
+0 (+0%)
At Close: May 27, 2022
Organicell Regenerative Medicine (OTCMKTS:BPSR) Stock Passes Below 50 Day Moving Average – Here’s What Happened
04:10am, Saturday, 11'th Apr 2026
Organicell Regenerative Medicine, Inc. (OTCMKTS:BPSR - Get Free Report) passed below its fifty day moving average during trading on Friday. The stock has a fifty day moving average of $2.18 and traded
Organicell Regenerative Medicine (OTCMKTS:BPSR) Share Price Crosses Below Fifty Day Moving Average – Should You Sell?
04:12am, Friday, 20'th Mar 2026
Organicell Regenerative Medicine, Inc. (OTCMKTS:BPSR - Get Free Report)'s share price passed below its fifty day moving average during trading on Thursday. The stock has a fifty day moving average of
Organicell Regenerative Medicine (OTCMKTS:BPSR) Shares Cross Below 50 Day Moving Average – Should You Sell?
04:20am, Wednesday, 11'th Feb 2026
Shares of Organicell Regenerative Medicine, Inc. (OTCMKTS:BPSR - Get Free Report) crossed below its 50-day moving average during trading on Tuesday. The stock has a 50-day moving average of $2.42 and
Organicell Launches Autologous Blood Derived Platform PPX™ – Patient Pure X™
07:30am, Wednesday, 09'th Jun 2021
MIAMI--(BUSINESS WIRE)---- $BPSR #biotech--Organicell launches a service platform for their first autologous product called Patient Pure X (PPX).
Organicell Signs an Exclusive Distribution Agreement with Apex Services in Pakistan
07:30am, Wednesday, 19'th May 2021
MIAMI--(BUSINESS WIRE)---- $BPSR #biotech--Organicell signs an exclusive distribution agreement with Apex Services Pakistan to import and distribute Zofin to hospitals and clinics.
MIAMI--(BUSINESS WIRE)---- $BPSR #biotech--Organicell and the CDC agree to use Zofin in experimental research for influenza.
‘Frontiers in Medicine' Publishes Organicell's Case Report Demonstrating the Use of Zofin™ in the Treatment of COVID-19 Patients
07:30am, Thursday, 18'th Mar 2021
MIAMI--(BUSINESS WIRE)---- $BPSR #biotech--Organicell announces the publication of a peer-reviewed case report analyzing the clinical outcomes of Zofin treatment in COVID-19 patients.
MIAMI--(BUSINESS WIRE)---- $BPSR #COPD--Organicell announces FDA approval of IND application for the use of its lead product, Zofin in treating chronic obstructive pulmonary disease (COPD).
The Forgotten Ones. Will Long-Haulers Be the Next Public Health Crisis?
07:30am, Tuesday, 12'th Jan 2021
MIAMI BEACH, Fla.--(BUSINESS WIRE)---- $BPSR #Zofin--Organicell will host a live online discussion on COVID-19 long-haulers.
